News
NICE rejects Perjeta in post-surgery breast cancer use - aga...
NICE has continued to reject Roche’s Perjeta (pertuzumab) in its use to prevent early-stage HER2-positive breast cancer from recurring after surgery, after reconsidering evidence in the lig
